Jie-Fei Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie-Fei Cheng has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Alex M. Nadzan
6 shared publicationsThomas Arrhenius
6 shared publicationsMi Chen
5 shared publicationsDavid Wallace
4 shared publicationsGary D. Lopaschuk
3 shared publicationsRick Barr
3 shared publications
Latest Publications
- 1 February 2008
- Published by Springer Nature in Molecular Diversity
- Vol. 12 (1) , 17-23
CCR1 antagonists
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported. Although some early CCR1 antagonists lacked the species cross reactivity that made in vivo animal model study difficult, efforts have been made to improve the compound potency in rodents. Recent identification of new and improved CCR1 antagonists has resulted in promising, in vivo efficacy in a variety of animal models of disease. While several early compounds have been withdrawn from clinical trials due to lack of efficacy, work continues to evaluate CCR1 antagonists in preclinical and clinical settings.
- 1 February 2008
- Published by Springer Nature in Molecular Diversity
- Vol. 12 (1) , 17-23
CCR1 antagonists
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported. Although some early CCR1 antagonists lacked the species cross reactivity that made in vivo animal model study difficult, efforts have been made to improve the compound potency in rodents. Recent identification of new and improved CCR1 antagonists has resulted in promising, in vivo efficacy in a variety of animal models of disease. While several early compounds have been withdrawn from clinical trials due to lack of efficacy, work continues to evaluate CCR1 antagonists in preclinical and clinical settings.
- 20 June 2007
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 70 (7) , 1195-1199
Hamigerols A and B, Unprecedented Polysulfate Sterol Dimers from the Mediterranean Sponge Hamigera hamigera
Two novel polysulfate sterol dimers, hamigerols A (1) and B (2), have been isolated from the Mediterranean sponge Hamigera hamigera. Their structures and stereochemistry have been assigned from the analysis of spectroscopic data.
- 20 June 2007
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 70 (7) , 1195-1199
Hamigerols A and B, Unprecedented Polysulfate Sterol Dimers from the Mediterranean Sponge Hamigera hamigera
Two novel polysulfate sterol dimers, hamigerols A (1) and B (2), have been isolated from the Mediterranean sponge Hamigera hamigera. Their structures and stereochemistry have been assigned from the analysis of spectroscopic data.
- 15 June 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (12) , 3473-3479
Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists
- 15 June 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (12) , 3473-3479
Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists
- 7 February 2007
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 70 (3) , 332-336
Myriaporones 1−4, Cytotoxic Metabolites from the Mediterranean Bryozoan Myriapora truncata
Four novel polyketide-derived metabolites, myriaporones 1, 2, 3, and 4, have been isolated from the Mediterranean bryozoan Myriapora truncata. Their structures and stereochemistry have been assigned from the analysis of spectroscopic data. The inseparable equilibrium mixture of myriaporones 3 and 4 showed 88% inhibition of L1210 murine leukemia cells at 0.2 microg/mL.
- 7 February 2007
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 70 (3) , 332-336
Myriaporones 1−4, Cytotoxic Metabolites from the Mediterranean Bryozoan Myriapora truncata
Four novel polyketide-derived metabolites, myriaporones 1, 2, 3, and 4, have been isolated from the Mediterranean bryozoan Myriapora truncata. Their structures and stereochemistry have been assigned from the analysis of spectroscopic data. The inseparable equilibrium mixture of myriaporones 3 and 4 showed 88% inhibition of L1210 murine leukemia cells at 0.2 microg/mL.
- 1 July 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (13) , 3484-3488
Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors
- 1 July 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (13) , 3484-3488
Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors
- 17 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (14) , 4055-4058
Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents
Discovery of 5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamides as a new class of malonyl-coenzyme A decarboxylase (MCD) inhibitors is described. tert-Butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate (5, CBM-301940) exhibited excellent potency and in vivo PK/ADME properties. It is the most powerful stimulant of glucose oxidation reported to date in isolated working rat hearts. Compound 5 improved the cardiac efficiency and function in a rat heart global ischemia/reperfusion model, suggesting MCD inhibitors may be useful for the treatment of ischemic heart diseases.
- 17 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (14) , 4055-4058
Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents
Discovery of 5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamides as a new class of malonyl-coenzyme A decarboxylase (MCD) inhibitors is described. tert-Butyl 3-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-4,5-dihydroisoxazole-3-carboxamido)butanoate (5, CBM-301940) exhibited excellent potency and in vivo PK/ADME properties. It is the most powerful stimulant of glucose oxidation reported to date in isolated working rat hearts. Compound 5 improved the cardiac efficiency and function in a rat heart global ischemia/reperfusion model, suggesting MCD inhibitors may be useful for the treatment of ischemic heart diseases.
- 11 February 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (5) , 1517-1525
Synthesis and Structure−Activity Relationship of Small-Molecule Malonyl Coenzyme A Decarboxylase Inhibitors
The discovery and structure-activity relationship of first-generation small-molecule malonyl-CoA decarboxylase (MCD; CoA = coenzyme A) inhibitors are reported. We demonstrated that MCD inhibitors increased malonyl-CoA concentration in the isolated working rat hearts. Malonyl-CoA is a potent, endogenous, and allosteric inhibitor of carnitine palmitoyltransferase-I (CPT-I), a key enzyme for mitochondrial fatty acid oxidation. As a result of the increase in malonyl-CoA levels, fatty acid oxidation rates were decreased and the glucose oxidation rates were significantly increased. Demonstration of in vivo efficacy of methyl 5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate (6u) in a pig ischemia model indicated that MCD inhibitors may be useful for treating ischemic heart diseases.
- 11 February 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (5) , 1517-1525
Synthesis and Structure−Activity Relationship of Small-Molecule Malonyl Coenzyme A Decarboxylase Inhibitors
The discovery and structure-activity relationship of first-generation small-molecule malonyl-CoA decarboxylase (MCD; CoA = coenzyme A) inhibitors are reported. We demonstrated that MCD inhibitors increased malonyl-CoA concentration in the isolated working rat hearts. Malonyl-CoA is a potent, endogenous, and allosteric inhibitor of carnitine palmitoyltransferase-I (CPT-I), a key enzyme for mitochondrial fatty acid oxidation. As a result of the increase in malonyl-CoA levels, fatty acid oxidation rates were decreased and the glucose oxidation rates were significantly increased. Demonstration of in vivo efficacy of methyl 5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate (6u) in a pig ischemia model indicated that MCD inhibitors may be useful for treating ischemic heart diseases.
- 1 February 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (3) , 695-700
Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors
- 1 February 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (3) , 695-700
Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors
- 17 May 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (10) , 2411-2415
Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors
- 17 May 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (10) , 2411-2415
Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors
- 1 May 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (10) , 2411-2415
Discovery and structure?activity relationship of coumarin derivatives as TNF-$alpha; inhibitors
- 1 May 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (10) , 2411-2415
Discovery and structure?activity relationship of coumarin derivatives as TNF-$alpha; inhibitors